Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center
Joined October 2011
- Tweets 172
- Following 213
- Followers 4,311
- Likes 905
25 Photos and videos
4 Jun 2024
In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. @YoninaMG @AlexiaIasonos
3 Jun 2024
Now online in @CD_AACR, a special commentary for #ASCO24: Optimus-Era Dose Finding for Rare Cancers - by @YoninaMG, Sean Devlin, @AlexiaIasonos, and @alexdrilon doi.org/10.1158/2159-8290.CD… @MSKCancerCenter
2
2
24
4,600
16 Nov 2023
Repotrectinib is FDA approved for ROS1 lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible. onclive.com/view/fda-approve…
1
30
104
16,783
Alexander Drilon MD retweeted
14 Aug 2023
Two research technician positions are immediately available in my lab @HopkinsMedicine @hopkinskimmel. You will be working on KRAS targeting in solid cancer. If interested, please apply here:
jobs.jhu.edu/job/Baltimore-R…
jobs.jhu.edu/job/Baltimore-R…
2
28
67
24,605
10 Jun 2023
Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations @Sandra_Misale!!
10 Jun 2023
I have some news, I'm thrilled to announce that the Misale Lab will open in July at @hopkinskimmel @HopkinsMedicine! We will work on resistance to therapy in solid tumors and we are hiring. Join us in this journey! #newPI #LabLaunch #cancer #kras #targetedtherapies #WomenInSTEM
3
19
4,824
3 Jun 2023
Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.
3 Jun 2023
Just published: #SHP2 Inhibition Sensitizes Diverse Oncogene-addicted Solid Tumors to Re-treatment with Targeted Therapy by @alexdrilon S. Michael Rothenberg and colleagues @MSKCancerCenter @PfizerOncMed. bit.ly/45HB06K #ASCO23
16
44
8,165
Alexander Drilon MD retweeted
10 Nov 2022
Out today in @CD_AACR our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blockade in colorectal cancer. Here’s the link of the paper shorturl.at/EOPT8 and a thread👇:
20
40
209
2 Oct 2022
Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to @NouraChoudhury @YoninaMG @NeilVasan and the many contributing authors!! amazon.com/gp/aw/d/B0B9T5NVL…
8
57
Alexander Drilon MD retweeted
4 Jun 2022
Aaaaand we're back!! 9 years really flew by since I was last here while working at #MSKCC; now as a #HOfellow @ClevelandClinic. Especially humbled to reconnect with a close friend and AMAZING mentor @alexdrilon at #ASCO22!!
2
1
24
3 May 2022
Excellent work from the Klebanoff lab on TCR development for an HLA-A*03:01 restricted public neoantigen generated in the context of a PIK3CA H1047L catalytic subunit hotspot mutation. rdcu.be/cMjvb
28 Apr 2022
A high-throughput platform to find rare #Tcells that recognize shared cancer #neoantigens identifies TCRs specific for a conserved and therapeutically actionable epitope in mutant PIK3CA, a common driver oncogene @KlebanoffLab @MSKCancerCenter @parkerici
nature.com/articles/s41591-0…
1
9
18 Mar 2022
RETi resistance in lung, thyroid & other cancers can be complex. This paper includes insights into the serial kinetics of resistance acquisition, the potential emergence of RET wild type populations & the frequency of polyclonal resistance. Proud to be part of this team!
6
51
6 Feb 2022
The first publication of larotrectinib in NTRK fusion lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world.
4 Feb 2022
.@alexdrilon et al. report on first analysis of the efficacy & safety of larotrectinib in pts with TRK fusion–positive lung cancer from a registrational data set. ORR of 73% ub 15 evaluable pts w OS of 40.7 months. Larotrectinib was well tolerated. fal.cn/3lTFs
7
54
196
Alexander Drilon MD retweeted
4 Jun 2021
Quick recap of today's presentation of Zeno in heavily pretreated NRG1 solid tumors. Efficacy observed across tumor types with ORR of 42% in PDAC. Thanks to @ASCO for the opportunity to present, @GarridoLagunaMD for an excellent discussion, collaborators, and patients. #ASCO2021
6
34
122
Alexander Drilon MD retweeted
4 Jun 2021
I’m honored to be among the #ConquerCancer Grant & Award Class of 2021 (CDA) and 2018 (YIA). Donors make these research opportunities possible. Give to the @ASCO CONQUERS CANCER Fund to help fuel the next generation of researchers bit.ly/ASCOCONQUERSCANCER_tw #ASCO21
Retweet this #ASCO21 #ConquerCancer collage and tag the doctors you see! Your gift to the #ASCOCONQUERSCANCER Fund supports Grant & Award recipients from around the globe 🌍🌎🌏 bit.ly/ASCOCONQUERSCANCER_tw
4
7
69
Alexander Drilon MD retweeted
4 Jun 2021
Congratulations to @NouraChoudhury on her @ConquerCancerFd @ASCO Young Investigator Award. I'm lucky to co-mentor her with @HelenaYu923 . She has an interesting trial combining amivantamab and lazertinib in patients with EGFR mutant NSCLC progressing in the CNS (almost open!).
2
4
46
Alexander Drilon MD retweeted
19 Apr 2021
RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET cancers. Through our partnership with @LUNGevity and a generous donation-matching program, we hope to fund lifesaving research. Join us at retpositive.org #RETcancer
ALT RETpositive Launch Press Release
1
14
32
8 Dec 2020
Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients. google.com/amp/s/finance.yah…
3
18
94
Alexander Drilon MD retweeted
12 Nov 2020
MET IHC is back from the dead! We wrote it off as a biomarker, but pl see latest study from our group lead by @alexdrilon & @RobinGuo5 which found MET expression to predict TKI response in MET Ex 14-altered NSCLC. Twists & turns of the ever-evolving NSCLC biomarker story!
4
18
67
3 Oct 2020
A call for rational type II TKI development. Seen through the lens of next-gen TRK inhibitor resistance in TRK fusion cancers. 🤓Highlights the utility of TKI type switching as a strategy for on-target resistance in oncogene-driven tumors. @EmilianoCocco2 @ScaltritiLab
1 Oct 2020
Here we go again. Great project led by
@EmilianoCocco2 and in collaboration with
@alexdrilon, @aventura71. @TheChandraGroup
and others. Mutations in the DFG domain of TRK receptors results in resistance to 2nd gen inhibitors. bit.ly/2GnM5mr
@sloan_kettering
13
42
26 Aug 2020
Wonderful team effort from many people around the world. I want to take a second to especially thank our patients and families without whom we could not have accomplished this. We are in your debt. Shout out to the RET Renegades! nejm.org/doi/full/10.1056/NE…
17
47
187
Alexander Drilon MD retweeted
18 Aug 2020
Excited to chair a free online lung cancer @OncLive webinar with @benlevylungdoc covering the latest topics in management of #NSCLC Wednesday, October 14, 6:30pm EST featuring expert faculty: @alexdrilon @IbiayiMD @Joshua_Reuss @kamarrone #LCSM
event.onclive.com/d/q7qppz
11
48